Aphria announced today that it has secured a $100 million raise, including a $75 million bought deal equity financing and $25 million in debt financing through a five–year term loan.
Tetra Bio-Pharma Inc. and Aphria Inc. announced plans today for the joint distribution of dried medical cannabis in the maritime provinces and Quebec.
Aphria Inc., a Health Canada Licensed Producer of medical cannabis products, comments on the proposed Cannabis Act announced today..
Aphria Inc. today reported its third quarter results, for the three and nine months ended February 28, 2017.
Aphria Inc. and MassRoots, Inc. are pleased to announce the early exercise of warrants by Aphria at US$0.90 per share for total proceeds to MassRoots of US$450,000.
Aphria through its subsidiary Aphria (Arizona) Inc., is pleased to announce that it made an additional investment of $3 million (USD) in Copperstate Farms Investors, LLC (“Investors”).
Aphria today announced that the common shares (the “Common Shares”) of the Company will begin trading on the Toronto Stock Exchange (“TSX”) as of the open of the market on March 22, 2017.
In light of recent media coverage, Aphria Inc. issued the following statement with respect to its ongoing commitment to providing pharmaceutical-grade cannabis that is free of chemical pesticides.
Aphria is pleased to announce it has closed its short form prospectus offering, on a bought deal basis.
Aphria is pleased to announce it has received conditional approval from the Toronto Stock Exchange (the "TSX") to graduate from the TSX Venture Exchange and…